Abstract
The objective of this study was to characterize the effect of albumin therapy on the expression of Toll-like receptor 4 (TLR 4), anti-inflammation cytokines and CD4+CD25+forkhead box P3 (Foxp3)+ regulatory T lymphocytes (Treg cells) in the ischemic brain and peripheral immune system after Middle Cerebral Artery Occlusion (MCAO). Adult male Kunming mice were subjected to MCAO, the suture was withdrawn 2 h later followed by an intravenous administration of 25% albumin (1.25 g/kg) or saline (5 ml/kg) through caudal vein. We demonstrated that albumin administration elevated the serum albumin level supranormally at 6 h and 24 h after MCAO in mice. In addition, we showed that both in the ischemic brain and in the spleen, albumin administration significantly depressed the increase of TLR 4 mRNA expression by quantitative real-time polymerase chain reaction (QRT-PCR), and significantly increase the anti-inflammatory related interleukin-10 (IL-10) and transforming growth factor beta1 (TGF-β1) mRNA expression by transcription-polymerase chain reaction (RT-PCR) after MCAO. In the spleen, compared to sham group, strong TLR 4 immunoreactivity was noted in the saline group; while compared to saline group, albumin administration markedly reduced the immunoreactivity of TLR 4 after MCAO by immunohistochemistry. Moreover, albumin administration significantly increased the percentage of Treg in spleen CD4+ cells by flow cytometry. In conclusion, the decrease of TLR 4 expression and the increase of Treg cell, IL-10, and TGF-β1 expression may partly contribute to the neuroprotective effect of albumin therapy on MCAO induced immune inflammatory responses.
Keywords: Albumin, Toll-like receptor 4, regulatory T cell, Middle Cerebral Artery Occlusion, interleukin-10, transforming growth factor beta1.
CNS & Neurological Disorders - Drug Targets
Title:Albumin Induces Neuroprotection Against Ischemic Stroke by Altering Toll-Like Receptor 4 and Regulatory T Cells in Mice
Volume: 12 Issue: 2
Author(s): Min Wang, Yongming Wang, Jing He, Siyu Wei, Na Zhang, Fengyong Liu, Xin Liu, Yi Kang and Xiaomei Yao
Affiliation:
Keywords: Albumin, Toll-like receptor 4, regulatory T cell, Middle Cerebral Artery Occlusion, interleukin-10, transforming growth factor beta1.
Abstract: The objective of this study was to characterize the effect of albumin therapy on the expression of Toll-like receptor 4 (TLR 4), anti-inflammation cytokines and CD4+CD25+forkhead box P3 (Foxp3)+ regulatory T lymphocytes (Treg cells) in the ischemic brain and peripheral immune system after Middle Cerebral Artery Occlusion (MCAO). Adult male Kunming mice were subjected to MCAO, the suture was withdrawn 2 h later followed by an intravenous administration of 25% albumin (1.25 g/kg) or saline (5 ml/kg) through caudal vein. We demonstrated that albumin administration elevated the serum albumin level supranormally at 6 h and 24 h after MCAO in mice. In addition, we showed that both in the ischemic brain and in the spleen, albumin administration significantly depressed the increase of TLR 4 mRNA expression by quantitative real-time polymerase chain reaction (QRT-PCR), and significantly increase the anti-inflammatory related interleukin-10 (IL-10) and transforming growth factor beta1 (TGF-β1) mRNA expression by transcription-polymerase chain reaction (RT-PCR) after MCAO. In the spleen, compared to sham group, strong TLR 4 immunoreactivity was noted in the saline group; while compared to saline group, albumin administration markedly reduced the immunoreactivity of TLR 4 after MCAO by immunohistochemistry. Moreover, albumin administration significantly increased the percentage of Treg in spleen CD4+ cells by flow cytometry. In conclusion, the decrease of TLR 4 expression and the increase of Treg cell, IL-10, and TGF-β1 expression may partly contribute to the neuroprotective effect of albumin therapy on MCAO induced immune inflammatory responses.
Export Options
About this article
Cite this article as:
Wang Min, Wang Yongming, He Jing, Wei Siyu, Zhang Na, Liu Fengyong, Liu Xin, Kang Yi and Yao Xiaomei, Albumin Induces Neuroprotection Against Ischemic Stroke by Altering Toll-Like Receptor 4 and Regulatory T Cells in Mice, CNS & Neurological Disorders - Drug Targets 2013; 12 (2) . https://dx.doi.org/10.2174/18715273113129990058
DOI https://dx.doi.org/10.2174/18715273113129990058 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies
Current Pharmaceutical Design Role of Lipoxins and Resolvins as Anti-Inflammatory and Proresolving Mediators in Colon Cancer
Current Molecular Medicine Patent Selections
Recent Patents on Nanotechnology Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Molecular Mechanisms of Ischemic Neuronal Cell Death - With Relevance to Alzheimers Disease
Current Alzheimer Research Acute Coronary Syndromes as Auto-Inflammatory Disorders
Current Pharmaceutical Design Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Mesenchymal Stem Cells as a Treatment Strategy for Coronavirus Disease 2019 (COVID-19): Need for Authority Regulations and Clinical Guidelines
Current Stem Cell Research & Therapy Update on Alzheimer’s Disease Therapeutics
Reviews on Recent Clinical Trials The Current Status of Novel PET Radio-Pharmaceuticals in Radiotherapy Treatment Planning of Glioma
Current Pharmaceutical Biotechnology Potential Role of Hydrogen Sulfide in the Pathogenesis of Vascular Dysfunction in Septic Shock
Current Vascular Pharmacology Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
Current Neuropharmacology Cardiac-Specific Expression of the Hepatocyte Growth Factor (HGF) Under the Control of a TnIc Promoter Confers a Heart Protective Effect After Myocardial Infarction (MI)
Current Gene Therapy Disruption of Circadian Rhythms and Sleep in Critical Illness and its Impact on the Development of Delirium
Current Pharmaceutical Design Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design